Investigation of the Therapeutic Effect of Silymarin, the Silybum marianum Medicinal Plant Extract, in an Empirically Induced in Vitro Model of Non-Alcoholic Fatty Liver Disease

Document Type : Original Article

Authors

Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a common digestive disorder that can cause some additional liver problems. Nowadays developing efficient therapies for the prevention and control of hepatic diseases is crucial. Recently, replacing synthetic drugs with natural herbal remedies has been more favored due to their ever-growing demand and public acceptance. Our goals in this study were the experimental induction of non-alcoholic fatty liver disease in the hepatocyte cell line and the evaluation of the therapeutic efficiency of silymarin, the Silybum marianum medicinal plant extract. The HepG2 cells were cultured in DMEM/F12 medium supplemented with 10% fetal bovine serum and 2 mM GlutaMAX. The effect of various concentrations of fructose in the induction of the fatty liver condition was assessed. Subsequently, the diseased hepatocytes were treated with different concentrations of silymarin. The therapeutic effect of silymarin was evaluated by fluorescent microscopy of the cells stained with a lipid-specific fluorescent dye and by quantifying the hepatic enzymes. Cultivation of HepG2 cells for seven days in the medium containing 30 mM fructose was found appropriate in the induction of the NAFLD condition. The lipid-specific staining, as well as the measurement of the hepatic enzymes, revealed the therapeutic efficiency of the 200 and 250 μM concentrations of silymarin. The experiments showed that Nile Red stain, silymarin, and DMSO were not notably cytotoxic. A high-energy diet provided by the added fructose in the culture medium was effective in resembling the NAFLD condition in HepG2 cells in Vitro. Furthermore, silymarin was found to be effective in curing the NAFLD condition in a time and dose-dependent manner.

Keywords

References

Abascal, K and Yarnell E. (2003). The many faces of Silybum marianum (Milk Thistle): Part 1 - treating cancer and hyperlipidemia and restoring kidney function. Alternative and Complementary Therapies. 9 (4): 170–175. Doi: https://doi.org/10.1089/107628003322256878.
Angulo P. (2002). Nonalcoholic fatty liver disease. The New England Journal of Medicine. 346 (16): 1221-1231. Doi: https://doi.org/10.1056/NEJMra011775.
Angulo P, Hui, JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO., Lenzi M, Adams L, Kench J, Therneau TM, Day CP. (2007). The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 45 (4): 846-854. Doi: https://doi.org/10.1002/hep.21496.
Askari F, Rashidkhani, B,  Hekmatdoost A. (2014). Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients. Nutrition Research. 34 (2): 143-148. Doi: https://doi.org/10.1016/j.nutres.2013.11.005.
Birjandi M, Ayatollahi SMT, Pourahmad S,  Safarpour AR. (2016). Prediction and diagnosis of non-Alcoholic fatty liver disease (NAFLD) and identification of its associated factors using the classification tree method. Iranian Red Crescent Medical Journal. 18 (11): e32858. Doi: https://doi.org/10.5812/ircmj.32858.
Cao P, Huang G, Yang Q, Guo J,  Su Z. (2016). The effect of chitooligosaccharides on oleic acid-induced lipid accumulation in HepG2 cells. Saudi Pharmaceutical Journal.24 (3): 292-298. Doi: https://doi.org/10.1016/j.jsps.2016.04.023.
Castera L, Friedrich-Rust M., Loomba R. (2019). Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 156 (5): 1264-1281.e4. Doi: https://doi.org/10.1053/j.gastro.2018.12.036.
Federico A, Dallio M, Loguercio C. (2017). Silymarin/Silybin and chronic liver disease: A marriage of many years. Molecules. 22 (2): 191. Doi: https://doi.org/10.3390/molecules22020191.
Ferenci P. (2016). Silymarin in the treatment of liver diseases: What is the clinical evidence? Clinical Liver Disease. 7 (1): 8-10. Doi: https://doi.org/10.1002/cld.522.
Fukumitsu S, Aida K, Shimizu H, Toyoda K. (2010). Flaxseed lignan lowers blood cholesterol and decreases liver disease risk factors in moderately hypercholesterolemic men. Nutrition Research. 30 (7): 441-446. Doi: https://doi.org/10.1016/j.nutres.2010.06.004.
Gallo D, Giacomelli S, Ferlini C, Raspaglio G, Apollonio P, Prislei S, Riva A, Morazzoni P, Bombardelli E, Scambia G. (2003). Antitumor activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer. European Journal of Cancer. 39 (16): 2403–2410. Doi: https://doi.org/10.1016/s0959-8049(03)00624-5.
Ghasemi R, Ghaffari SH, Momeny M, Pirouzpanah S, Yousefi M, Malehmir M, Alimoghaddam K, Ghavamzadeh A. (2013). Multitargeting and antimetastatic potentials of silibinin in human HepG-2 and PLC/PRF/5 hepatoma cells. Nutrition and Cancer. 65 (4): 590-599. Doi: https://doi.org/10.1080/01635581.2013.770043.
Ghosh N, Ghosh R, Mandal V, Mandal SC. (2011). Recent advances in herbal medicine for the treatment of liver diseases. Pharmaceutical Biology. 49 (9): 970-988. Doi: https://doi.org/10.3109/13880209.2011.558515.
Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. (2008). Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 57 (10): 1441-1447. Doi: https://doi.org/10.1136/gut.2007.146019.
Im AR, Kim Y H, Lee HW, Song KH. (2016). Water Extract of Dolichos lablab Attenuates Hepatic Lipid Accumulation in a Cellular Nonalcoholic Fatty Liver Disease Model. Journal of Medicinal Food. 19 (5): 495-503. Doi: https://doi.org/10.1089/jmf.2015.3623.
Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstråle M, Groop L, Orho-Melander M, Yki-Järvinen H. (2009). Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 137 (3): 865-872. Doi: https://doi.org/10.1053/j.gastro.2009.06.005.
Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, Lee HS. (2010). Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. Digestive and Liver Disease, 42 (7): 503-508. Doi: https://doi.org/10.1016/j.dld.2009.08.002.
Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. (2006). Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver International: Official Journal of the International Association for the Study of the Liver. 26 (2): 151-156. Doi: https://doi.org/10.1111/j.1478-3231.2005.01209.x.
Pesakhov S, Khanin M, Studzinski GP, Danilenko M. (2010). Distinct combinatorial effects of the plant polyphenols curcumin, carnosic acid, and silibinin on proliferation and apoptosis in acute myeloid leukemia cells. Nutrition and Cancer. 62 (6): 811-824. Doi: https://doi.org/10.1080/01635581003693082.
Pezeshki A, Safi S, Feizi A, Askari G, Karami F. (2016). The Effect of Green Tea Extract Supplementation on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease. International Journal of Preventive Medicine. 7: 28. Doi: https://doi.org/10.4103/2008-7802.173051.
Pratt DS, Kaplan MM. (2000). Evaluation of abnormal liver-enzyme results in asymptomatic patients. The New England Journal of Medicine. 342 (17): 1266-1271. Doi: https://doi.org/10.1056/NEJM200004273421707.
Reddy JK, Rao MS. (2006). Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. American Journal of Physiology. Gastrointestinal and Liver Physiology. 290 (5): G852-858. Doi: https://doi.org/10.1152/ajpgi.00521.2005.
Ricchi M, Odoardi MR, Carulli L, Anzivino C, Ballestri S, Pinetti A, Fantoni LI, Marra F, Bertolotti M, Banni S, Lonardo A, Carulli N, Loria P. (2009). Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. Journal of Gastroenterology and Hepatology. 24 (5): 830-840. Doi: https://doi.org/10.1111/j.1440-1746.2008.05733.x.
Shukla Y, Singh M. (2007). Cancer preventive properties of ginger: A brief review. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association. 45 (5): 683-690. Doi: https://doi.org/10.1016/j.fct.2006.11.002.
Sobolová L, Skottová N, Vecera R, Urbánek K. (2006). Effect of silymarin and its polyphenolic fraction on cholesterol absorption in rats. Pharmacological Research. 53 (2): 104-112. Doi: https://doi.org/10.1016/j.phrs.2005.09.004.
Tiwari P, Kumar A, Balakrishnan S, Kushwaha HS, Mishra KP. (2011). Silibinin-induced apoptosis in MCF7 and T47D human breast carcinoma cells involves caspase-8 activation and mitochondrial pathway. Cancer Investigation. 29 (1): 12-20. Doi: https://doi.org/10.3109/07357907.2010.535053.
Toklu HZ, Tunali-Akbay T, Erkanli G, Yüksel M, Ercan F, Sener G. (2007). Silymarin, the antioxidant component of Silybum marianum, protects against burn-induced oxidative skin injury. Burns: Journal of the International Society for Burn Injuries. 33 (7): 908-916. Doi: https://doi.org/10.1016/j.burns.2006.10.407.
Willebrords J, Pereira IVA, Maes M, Yanguas SC, Colle I, Van Den Bossche B, Da silva TC, Oliveira CP, Andraus W, Alves VAF, Cogliati B, Vinken M. (2015). Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Progress in Lipid Research. 59: 106-125. Doi: https://doi.org/10.1016/j.plipres.2015.05.002.
Yu AS and Keeffe EB. (2002). Nonalcoholic fatty liver disease. Reviews in Gastroenterological Disorders. 2 (1): 11-19. PMID: 12122975.
Zolfaghari H, Jafarian, K, Iraj B, Askari G. (2014). The role of mega-3 fatty acids on the prevention and treatment of nonalcoholic fatty liver disease: a review of published papers. Journal of Isfahan Medical School. 32 (276): 243-255.
Plant, Algae, and Environment
Volume 7, Issue 2
2023
Pages 1184-1196

Files

Share

How to cite

Statistics